<p>The HHL genomics study uses a systems approach to develop models integrating clinical and genomic data. Previously we developed and tested an approach known as the SAMARA (Supporting A Multidisciplinary Approach to Research in Atherosclerosis) project that applied recent advances in biomedical and computational sciences at The University of North Carolina at Chapel Hill to develop a deeper understanding of human cardiovascular disease (CVD). The Heart-Healthy Lenoir Project expands these studies into the community, using this methodology to: 1) determine the prevalence of genomic risk signatures in high-risk community populations using genome-wide Single Nucleotide Polymorphism (SNP) analysis; 2) develop novel genomic models incorporating high-risk features in this population; and 3) determine whether genomic signatures can be used to predict responsiveness to interventions that underlie CVD disparities.</p> <p>DNA was obtained from participants enrolled in two of the HHL clinical trials, 1) Improving Care for Patients With High Blood Pressure (<a href="https://clinicaltrials.gov/ct2/show/NCT01425515">NCT01425515</a>) or 2) Heart-Healthy Lenoir Lifestyle Study (<a href="https://clinicaltrials.gov/ct2/show/NCT01433484">NCT01433484</a>). Participants could enroll in both trials concurrently.</p>

Heart Healthy Lenoir (HHL) Genomics Study

Description

Applying For Access

Summary